Skip to main
MRK
MRK logo

Merck (MRK) Stock Forecast & Price Target

Merck (MRK) Analyst Ratings

Based on 32 analyst ratings
Buy
Strong Buy 31%
Buy 28%
Hold 38%
Sell 0%
Strong Sell 3%

Bulls say

Merck & Co is projected to experience strong growth in the latter half of 2025 and into 2026 and 2027, supported by a robust portfolio that includes the Capvaxive pneumococcal vaccine and RSV antibody, which are anticipated to help the company capture significant market share. The optimistic outlook for Keytruda's subcutaneous formulation, coupled with expected revenues from new products like clesrovimab for RSV and islatravir for HIV treatment, positions Merck advantageously, even as it prepares for the loss of exclusivity on certain products. Additionally, ongoing positive trial results for Winrevair and MK-8527 could further enhance Merck’s revenue streams and overall market presence, solidifying its positive financial trajectory.

Bears say

Merck & Co. is facing a fundamentally negative outlook primarily due to anticipated significant declines in Keytruda sales as a result of biosimilar competition and Medicare negotiations, with projections indicating a potential decrease of up to 58% post-loss of exclusivity. Additionally, the company's financial performance is being impacted by underwhelming sales figures from its other products, such as Winrevair, which fell short of consensus estimates and is modeled to experience a considerable reduction in US sales by 2030. The overall decrease in business development activity and the challenges in effectively transitioning Keytruda to subcutaneous formulations further exacerbate concerns regarding revenue sustainability and market positioning.

Merck (MRK) has been analyzed by 32 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 28% recommend Buy, 38% suggest Holding, 0% advise Selling, and 3% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merck (MRK) Forecast

Analysts have given Merck (MRK) a Buy based on their latest research and market trends.

According to 32 analysts, Merck (MRK) has a Buy consensus rating as of Jun 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $110.34, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $110.34, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merck (MRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.